Table 1.
Study group demographics
| Variable | stroke patients (n = 35) | controls (n = 16) | p value | |
|---|---|---|---|---|
| Males | 18 (51.4%) | 7 (43.8%) | n.s. | |
| Age median (median, range) | 77 (70.9, 26–98) | 76.5 (70.7, 31–99) | n.s. | |
| Anticoagulation | yes | 13 (37.1%) | 6 (37.5%) | n.s. |
| Type of anticoagulation | n.s. | |||
| ASS | 7 (20.0%) | 3 (18.8%) | ||
| Clopidogrel | 0 (0.0%) | 0 (0.0%) | ||
| ASS+Clopid | 1 (2.8%) | 0 (0.0%) | ||
| VKA | 2 (5.6%) | 1 (6.7%) | ||
| NOAC | 3 (8.5%) | 2 (12.5%) | ||
| History of previous stroke | yes | 6 (17.1%) | 2 (12.5%) | n.s. |
| History of AFa | yes | 7 (20.0%) | 3 (18.8%) | n.s. |
| CCIb | n.s. | |||
| 0–1 | 18 (51.4%) | 9 (60.0%) | ||
| 2–3 | 15 (42.8%) | 6 (37.5%) | ||
| >3 | 2 (5.7%) | 1 (6.7%) | ||
| Art.hypertension | yes | 17 (48.5%) | 10 (62.5%) | n.s. |
| Diabetes | yes | 5 (14.2%) | 3 (18.8%) | n.s. |
| Renal disease | yes | 1 (2.8%) | 1 (6.7%) | n.s. |
| Liver disease | yes | 2 (5.7%) | 2 (12.5%) | n.s. |
| Pulmonary disease | yes | 4 (11.4%) | 2 (12.5%) | n.s. |
| Myocardial infarct /heart failure | yes | 8 (22.8%) | 3 (18.8%) | n.s. |
| PVDc | yes | 3 (8.5%) | 1 (6.7%) | n.s. |
| Cancerd | yes | 5 (14.2%) | 2 (12.5%) | n.s. |
aAF Atrial fibrillation, bCCI Charlson Comorbidity Index, cPVD Peripheral vascular disease or bypass, d Non active cancer disease diagnosed at least 5 years before MT